Penn Capital Management Company LLC Buys New Holdings in Aquestive Therapeutics, Inc. $AQST

Key Points

• Penn Capital Management Company LLC has acquired a new position in Aquestive Therapeutics, Inc. by purchasing 86,618 shares valued at approximately $251,000 in the first quarter.
• Aquestive Therapeutics reported q2 earnings with a loss of ($0.14), slightly better than the expected loss of ($0.18), and had quarterly revenue of $10 million.
• Analysts have given Aquestive Therapeutics a consensus rating of "Moderate Buy" with a target price of approximately $10.14, reflecting positive market sentiment.

Penn Capital Management Company LLC purchased a new position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 86,618 shares of the company's stock, valued at approximately $251,000. Penn Capital Management Company LLC owned about 0.09% of Aquestive Therapeutics at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Bank of America Corp DE grew its holdings in shares of Aquestive Therapeutics by 905.2% during the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock worth $2,457,000 after purchasing an additional 621,614 shares during the period. Stifel Financial Corp lifted its position in Aquestive Therapeutics by 315.4% during the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock valued at $1,419,000 after buying an additional 302,617 shares in the last quarter. Nuveen LLC acquired a new position in Aquestive Therapeutics during the first quarter valued at approximately $686,000. Harvey Capital Management Inc. grew its stake in Aquestive Therapeutics by 86.8% during the first quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock worth $1,449,000 after buying an additional 232,180 shares during the period. Finally, Stonepine Capital Management LLC purchased a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $570,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $3.98 on Friday. Aquestive Therapeutics, Inc. has a 12-month low of $2.12 and a 12-month high of $5.80. The company has a market capitalization of $396.89 million, a price-to-earnings ratio of -5.69 and a beta of 1.99. The firm's fifty day moving average price is $3.82 and its 200 day moving average price is $3.18.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Zacks Research upgraded shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. Oppenheimer assumed coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $7.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $10.14.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.